Drugs / Radiprodil
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT07457229 | Mar 2026 → May 2027 expected | — | GRIN Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT06975605 | May → Jul 2025 | isolated focal cortical dysplasia, tuberous sclerosis | GRIN Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06965881 | May → Jul 2025 | isolated focal cortical dysplasia, tuberous sclerosis | GRIN Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT05818943 | Mar 2023 → Nov 2026 expected | GRIN-related complex neurodevelopmental disorder | GRIN Therapeutics, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02647697 | Jan → Feb 2016 | — | UCB Biopharma S.P.R.L. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06392009 | Jul 2024 → Jun 2026 overdue | isolated focal cortical dysplasia type II, tuberous sclerosis | GRIN Therapeutics, Inc. | Active not recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02829827 | Dec 2017 → Oct 2018 | infantile spasms | UCB Biopharma S.P.R.L. | Terminated | No outcome recorded |
| Phase 2 | NCT00838799 | Feb 2009 → Apr 2010 | diabetic polyneuropathy | Forest Laboratories | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07224581 | Jan 2026 → May 2027 expected | GRIN-related complex neurodevelopmental disorder | GRIN Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Radiprodil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06392009 ↗ |
| Known as | RGH-896 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00838799 ↗ |
| Action | Inhibit | “negative allosteric modulator” NCT05818943 ↗ |
| Modality | Small molecule | — CHEMBL182066 ↗ |
| Route | Oral | “Route of Administration: oral use” NCT02647697 ↗ |